Private Companies Are Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Biggest Owners and Were Hit After Market Cap Dropped CN¥415m

Simply Wall StDec 17 17:11 ET

Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?

Simply Wall StNov 1 21:15 ET

Hendy Pharmaceuticals: third quarter report 2024

SZSIOct 27 12:00 ET · Announcements

Hengdi Pharmaceutical (301211.SZ): The net income for the first three quarters was 74.6615 million yuan, a year-on-year decrease of 48.34%.

On October 27, Hengdi Pharmaceutical (301211.SZ) announced that in the first three quarters of 2024, it achieved revenue of 0.334 billion yuan, a decrease of 38.43% year-on-year; the net income attributable to shareholders of the listed company was 74.6615 million yuan, a decrease of 48.34%, with a basic earnings per share of 0.26 yuan.

Gelonghui FinanceOct 27 04:43 ET

Hengdi Pharmaceutical (301211.SZ) released its performance for the first three quarters, with a net income of 74.6615 million yuan, a year-on-year decrease of 48.34%.

Hengdi Pharmaceutical (301211.SZ) released the third quarter report for 2024, with revenue for the first three quarters reaching ...

Zhitong FinanceOct 27 04:11 ET

Subdued Growth No Barrier To Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Price

Simply Wall StSep 27 19:59 ET